Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.

Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL; CHAMPION Investigators.

J Am Coll Cardiol. 2017 Jan 17;69(2):176-185. doi: 10.1016/j.jacc.2016.10.055.

PMID:
28081827
2.

Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.

Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators.

JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775. Erratum in: JAMA. 2016 Jul 19;316(3):350. JAMA. 2016 Jul 19;316(3):350.

3.

Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.

Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators.

JAMA. 2015 Mar 17;313(11):1113-21. doi: 10.1001/jama.2015.1671. Erratum in: JAMA. 2016 Jul 5;316(1):105. JAMA. 2016 Jul 5;316(1):105. JAMA. 2015 Jun 2;313(21):2185.

4.

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators.

N Engl J Med. 2014 Dec 4;371(23):2155-66. doi: 10.1056/NEJMoa1409312. Epub 2014 Nov 16.

5.

Using Big Data to Track Trends in Medical Practice.

Kolacevski A, Mann JT, Hauser R, Schilsky RL.

J Oncol Pract. 2015 Jan;11(1):69-70. doi: 10.1200/JOP.2014.001541. Epub 2014 Aug 19. No abstract available.

PMID:
25139800
6.

ASCO's approach to a learning health care system in oncology.

Sledge GW, Hudis CA, Swain SM, Yu PM, Mann JT, Hauser RS, Lichter AS.

J Oncol Pract. 2013 May;9(3):145-8. doi: 10.1200/JOP.2013.000957. Review.

7.

Strategies for multivessel revascularization in patients with diabetes.

Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S 3rd, Bertrand M, Fuster V; FREEDOM Trial Investigators.

N Engl J Med. 2012 Dec 20;367(25):2375-84. doi: 10.1056/NEJMoa1211585. Epub 2012 Nov 4.

8.

A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: final results of the ZoMaxx II trial.

Gray WA, Yeung AC, Cutlip DE, Popma JJ, Fitzgerald PJ, Williams DO, Heuer H, O'Shaughnessy CD, Overlie PA, Mann JT, Cannon LA, Hermiller JB, Henry TD, Whitbourn R, Stuckey TD, Midei MG, Coe J, Schwartz LB.

Int J Cardiol. 2012 May 17;157(1):96-101. doi: 10.1016/j.ijcard.2011.05.061. Epub 2011 Jun 11.

PMID:
21658783
9.

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.

CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S.

N Engl J Med. 2010 Sep 2;363(10):930-42. doi: 10.1056/NEJMoa0909475. Erratum in: N Engl J Med. 2010 Oct 14;363(16):1585.

10.

Protected carotid stenting in high-risk patients: results of the SpideRX arm of the carotid revascularization with ev3 arterial technology evolution trial.

Safian RD, Jaff MR, Bresnahan JF, Foster M, Bacharach JM, Yadav J, Joye J, Myla S, Kassab E, Mann JT, Ansel GM; CREATE SpideRX Trial Investigators.

J Interv Cardiol. 2010 Oct;23(5):491-8. doi: 10.1111/j.1540-8183.2010.00578.x.

PMID:
20624206
11.

Intravenous platelet blockade with cangrelor during PCI.

Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA; CHAMPION PLATFORM Investigators.

N Engl J Med. 2009 Dec 10;361(24):2330-41. doi: 10.1056/NEJMoa0908629.

12.

Chronic arterial responses to overlapping paclitaxel-eluting stents: insights from serial intravascular ultrasound analyses in the TAXUS-V and -VI trials.

Aoki J, Mintz GS, Weissman NJ, Mann JT, Cannon L, Greenberg J, Grube E, Masud AR, Koglin J, Mandinov L, Stone GW.

JACC Cardiovasc Interv. 2008 Apr;1(2):161-7. doi: 10.1016/j.jcin.2007.12.005.

13.

Impact of mild or moderate renal insufficiency on the intravascular ultrasonic analysis of chronic vascular response to paclitaxel-eluting and bare-metal stents (from the TAXUS IV, V, and VI trials).

Aoki J, Mintz GS, Weissman NJ, Mandinov L, Grube E, Dawkins KD, Ellis SG, Greenberg J, Yu A, Mann JT, Cannon L, Cambier PA, Stone GW.

Am J Cardiol. 2008 Oct 15;102(8):1009-16. doi: 10.1016/j.amjcard.2008.05.051. Epub 2008 Jul 26.

PMID:
18929701
14.

Femoral access bleeding complications remain an important cause of morbidity and mortality in patients undergoing interventional procedures.

Mann JT 3rd.

Catheter Cardiovasc Interv. 2008 Apr 1;71(5):655; author reply 656. doi: 10.1002/ccd.21325. No abstract available.

PMID:
18360859
15.

Unprotected left main disease managed with drug-eluting stents: long-term outcome of 100 patients with increased surgical risk.

Wood FO, Saylors EK, Schneider JE, Jobe RL, Mann JT 3rd.

Catheter Cardiovasc Interv. 2008 Mar 1;71(4):533-8. doi: 10.1002/ccd.21447.

PMID:
18307224
16.

Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial.

Pinto DS, Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Mehran R, Na Y, Turco M, Caputo R, Popma JJ, Cutlip DE, Russell ME, Cohen DJ; TAXUS-IV Investigators.

J Am Coll Cardiol. 2006 Jul 4;48(1):32-6. Epub 2006 Jun 9.

17.

Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.

Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME; TAXUS V Investigators.

JAMA. 2005 Sep 14;294(10):1215-23.

PMID:
16160130
18.

A randomized, controlled trial of saphenous vein graft intervention with a filter-based distal embolic protection device: TRAP trial.

Dixon SR, Mann JT, Lauer MA, Casale PN, Dippel EJ, Strumpf RK, Feldman RL, Shear W, Resar JR, Zimmer SD, O'Neill WW; TRAP Investigators.

J Interv Cardiol. 2005 Aug;18(4):233-41.

PMID:
16115151
19.

Problems and complications of the transradial approach for coronary interventions: a review.

Bazemore E, Mann JT 3rd.

J Invasive Cardiol. 2005 Mar;17(3):156-9. Review. No abstract available.

PMID:
15867445
20.

Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial.

Weissman NJ, Koglin J, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Kutcher M, Wong SC, Strickland W, Mooney M, Russell ME, Ellis SG, Stone GW.

J Am Coll Cardiol. 2005 Apr 19;45(8):1201-5.

Supplemental Content

Loading ...
Support Center